Table 3.
Resectability criteria and societies
Vessel involvement
|
NCCN 2019
|
MDACC
|
ACTO
|
AHPBA/SSAT/SSO
|
CA abutment (≤ 180°) | Borderline | Borderline | Borderline | Unresectable |
CA encasement (> 180°) | Borderline (body/tail); locally advanced (head/uncinate) | Unresectable | Unresectable | Unresectable |
SMA abutment (< 180°); SMA encasement (> 180°); CHA abutment or encasement | Borderline; Locally advanced; Borderline | Borderline; Unresectable; Borderline | Borderline; Unresectable; Borderline | Borderline; Unresectable; Borderline |
PV/SMV encasement (> 180°) or abutment (≤ 180°) with contour abnormality | Borderline | Borderline | Borderline | Borderline |
ACTO: Alliance for Clinical Trials in Oncology; AHPBA: American Hepato-Pancreato-Biliary Association; CA: Celiac artery; CHA: Common hepatic artery; MDACC: The University of Texas MD Anderson Cancer Center; NCCN: National Comprehensive Cancer Network; PV: Portal vein; SMA: Superior mesenteric artery; SMV: Superior mesenteric vein; SSAT: Society for Surgery of the Alimentary Tract; SSO: Society for Surgical Oncology.